Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

被引:6
|
作者
Trudeau, Jeremiah J. [1 ]
He, Jianming [1 ]
Rose, Esther [2 ]
Panter, Charlotte [3 ]
Randhawa, Sharan [3 ]
Gater, Adam [3 ]
机构
[1] Janssen Global Serv LLC, 700 US 202 South, Raritan, NJ 08869 USA
[2] Janssen Pharmaceut LLC, Raritan, NJ 08869 USA
[3] Adelphi Values, Bollington, Cheshire, England
关键词
Myelodysplastic syndrome; Patient reported outcomes; FACT-An; QUALMS; Health-related quality of life; QUALITY-OF-LIFE; PROGNOSTIC SCORING SYSTEM; LEUKEMIC EVOLUTION; 5Q DELETION; SURVIVAL; MDS; ANEMIA; SYMPTOMS; CRITERIA; IMPACT;
D O I
10.1186/s41687-020-00235-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS. Methods In this cross-sectional, qualitative study, 16 patients aged >= 18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments. Results The median age of participants was 67.5 years (range: 51-91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate. Conclusion Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
    Jeremiah J. Trudeau
    Jianming He
    Esther Rose
    Charlotte Panter
    Sharan Randhawa
    Adam Gater
    [J]. Journal of Patient-Reported Outcomes, 4
  • [2] Azacitidine in lower-risk myelodysplastic syndromes
    Santini, Valeria
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
  • [3] DEVELOPMENT OF CORE PATIENT-REPORTED OUTCOMES IN MYELODYSPLASTIC SYNDROMES
    Stojkov, Igor
    Conrads-Frank, Annette
    Rochau, Ursula
    Koinig, Karin
    Arvandi, Marjan
    Puntscher, Sibylle
    van Marrewijk, Corine
    Fenaux, Pierre
    de Witte, Theo
    Efficace, Fabio
    Siebert, Uwe
    Stauder, Reinhard
    [J]. MEDICAL DECISION MAKING, 2020, 40 (05) : E424 - E425
  • [4] Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
    Fenaux, Pierre
    Platzbecker, Uwe
    Mufti, Ghulam J.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Falantes, Jose F.
    Arrizabalaga, Beatriz
    Salvi, Flavia
    Giai, Valentina
    Vyas, Paresh
    Bowen, David
    Selleslag, Dominik
    DeZern, Amy E.
    Jurcic, Joseph G.
    Germing, Ulrich
    Goetze, Katharina S.
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Cluzeau, Thomas
    Voso, Maria-Teresa
    Mazure, Dominiek
    Vellenga, Edo
    Greenberg, Peter L.
    Hellstrom-Lindberg, Eva
    Zeidan, Amer M.
    Ades, Lionel
    Verma, Amit
    Savona, Michael R.
    Laadem, Abderrahmane
    Benzohra, Aziz
    Zhang, Jennie
    Rampersad, Anita
    Dunshee, Diana R.
    Linde, Peter G.
    Sherman, Matthew L.
    Komrokji, Rami S.
    List, Alan F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02): : 140 - 151
  • [5] How to manage lower-risk myelodysplastic syndromes
    Sekeres, M. A.
    [J]. LEUKEMIA, 2012, 26 (03) : 390 - 394
  • [6] Lowering the boom on lower-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Patel, Bhumika J.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 367 - 372
  • [7] Evolving therapies for lower-risk myelodysplastic syndromes
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    [J]. ANNALS OF HEMATOLOGY, 2020, 99 (04) : 677 - 692
  • [8] Management of patients with lower-risk myelodysplastic syndromes
    Andrew M. Brunner
    Heather A. Leitch
    Arjan A. van de Loosdrecht
    Nicolas Bonadies
    [J]. Blood Cancer Journal, 12
  • [9] Diagnostic algorithm for lower-risk myelodysplastic syndromes
    Mufti, Ghulam J.
    McLornan, Donal P.
    van de Loosdrecht, Arjan A.
    Germing, Ulrich
    Hasserjian, Robert P.
    [J]. LEUKEMIA, 2018, 32 (08) : 1679 - 1696
  • [10] Raising the bar for lower-risk myelodysplastic syndromes
    Venugopal, Sangeetha
    Sekeres, Mikkael A. A.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (06) : 1082 - 1091